Industry Briefs: Feb. 13, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Feb. 13, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Bend Research has entered into a licensing agreement with Eli Lilly, under which Bend Research will make its proprietary spray-dried dispersion technology available to Lilly. Read More

BioDiem has licensed its live attenuated influenza virus (LAIV) vaccine technology to China-based Changchun BCHT Biotechnology. Read More

Carbogen Amcis has announced that its Bubendorf, Switzerland, API-manufacturing site has successfully completed a September 2011 FDA cGMP inspection. Read More

Discovery Labs has entered into a definitive agreement with Lacey Manufacturing, a unit of Precision Engineered Products, to manufacture and supply product for the commercial introduction of Afectair, a series of proprietary ventilator circuit–patient interface connectors and related componentry for the delivery of inhaled therapies to patients requiring ventilatory support. Read More

Quintiles has launched two services—Strategic Drug Development and Consulting at Quintiles—for the development and commercialization of new medications in Asia. Read More

Valeant Pharmaceuticals has agreed to acquire the ophthalmic biotechnology company Eyetech. Read More

People News

Cobra Biologics has appointed Sharon Brownlow and Partick Lansky as business development managers, and added nonexecutive directors Elisabeth Lindner, Carl Johan Sundberg, and Jinyue Wang, to its board. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here